Compare · NVO vs SYRE
NVO vs SYRE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Spyre Therapeutics Inc. (SYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 24.0x SYRE ($8.98B).
- Over the past year, NVO is down 29.3% and SYRE is up 499.5% - SYRE leads by 528.8 points.
- NVO has hit the wire 4 times in the past 4 weeks while SYRE has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 10 for SYRE).
- Company
- Novo Nordisk A/S
- Spyre Therapeutics Inc.
- Price
- $48.78+1.22%
- $102.18+2.16%
- Market cap
- $215.95B
- $8.98B
- 1M return
- +2.89%
- +18.47%
- 1Y return
- -29.29%
- +499.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SYRE
- Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $658,040 worth of shares (7,500 units at $87.74) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Sloan Sheldon exercised 8,334 shares at a strike of $27.46 and sold $730,896 worth of shares (8,334 units at $87.70) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Turtle Cameron sold $1,315,346 worth of shares (15,000 units at $87.69) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 582,540 units (SEC Form 4)
- Spyre Therapeutics Announces Grants of Inducement Awards
- Chief Financial Officer Burrows Scott L exercised 15,000 shares at a strike of $14.50 and sold $1,307,000 worth of shares (15,000 units at $87.13) (SEC Form 4)
- SEC Form S-3ASR filed by Spyre Therapeutics Inc.
- Director Fairmount Funds Management Llc converted options into 666,680 shares and sold $399,658,667 worth of shares (4,684,781 units at $85.31) (SEC Form 4)
- Director Henderson Michael Thomas sold $2,000,000 worth of shares (20,000 units at $100.00) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 68,606 units (SEC Form 4)
- Spyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients